- Pharmaceutical companies
- Daiichi Sankyo Co., Ltd.
Daiichi Sankyo Co., Ltd.
Phone: +81 3-6225-1111
Web: https://www.daiichisankyo.com
Native name | 第一三共株式会社 |
---|---|
Romanized name | Daiichi Sankyō kabushiki gaisha |
Type | Public KK |
Traded as | TYO: 4568 TOPIX Large 70 Component TOPIX 100 Component Nikkei 225 Component |
Industry | Pharmaceutical |
Predecessors |
|
Founded | Tokyo, Japan (2005) (by merger) |
Headquarters | Daiichi Sankyo Building A/B 3-5-1, Nihonbashi-honcho, Chūō-ku, Tokyo 103-8426, Japan |
Key people |
|
Products |
|
Revenue | $ 9.028 billion USD (FY 2019) (¥ 981.8 billion JPY) (FY 2019) |
Net income | $ 1.276 billion USD (FY 2019) (¥ 138.8 billion JPY) (FY 2019) |
Number of employees | 15,348 (as of March 2020) |
Website | http://www.daiichisankyo.com |
Daiichi Sankyo Company, Limited (Japanese: 第一三共株式会社, Hepburn: Daiichi Sankyō Kabushiki-gaisha) is a global pharmaceutical company and the second-largest pharmaceutical company in Japan. It achieved JPY 981.8 billion in revenue in 2019. The company owns the American biotechnology company Plexxikon, American pharmaceutical company American Regent, German biotechnology company U3 Pharma, and recently sold Ranbaxy Laboratories in India. Daiichi Sankyo Co., Ltd. is the producer of Benicar (Olmesartan), an angiotensin II receptor antagonist and top selling drug in the U.S. Global sales of Olmesartan in 2013 were 300.2 billion yen.
Daiichi Sankyo, Inc. (DSI) began operating in the U.S. in 2006. It is the U.S. subsidiary of Daiichi Sankyo Company, Limited, and a member of the Daiichi Sankyo Group. The organization, which includes U.S. commercial operations and global clinical development (Daiichi Sankyo Pharma Development), is headquartered in Basking Ridge, New Jersey.
Daiichi Sankyo Europe, GmbH (DSE), the European subsidiary, is headquartered in Munich, Germany. The organization is responsible for development and manufacturing for 12 European countries.
Daiichi Sankyo Company, Limited is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).
For detailed contact information visit location pages below.
Daiichi Sankyo Co., Ltd.'s locations around the world
Clinical Trials sponsored by Daiichi Sankyo Co., Ltd.
-
Daiichi Sankyo Co., Ltd.모병
-
Daiichi Sankyo Co., Ltd.모집하지 않고 적극적으로
-
Daiichi Sankyo Co., Ltd.Daiichi Sankyo모집하지 않고 적극적으로
-
Daiichi SankyoDaiichi Sankyo Co., Ltd.모집하지 않고 적극적으로비소세포폐암 전이성 | 표피 성장 인자 수용체에 돌연변이가 있는 비소세포폐암미국, 스페인, 대한민국, 프랑스, 영국, 대만, 호주, 일본, 중국, 네덜란드, 이탈리아, 독일, 오스트리아, 벨기에, 불가리아, 싱가포르
-
Daiichi Sankyo Co., Ltd.모집하지 않고 적극적으로
-
Daiichi SankyoAstraZeneca; Daiichi Sankyo Co., Ltd.모집하지 않고 적극적으로유방암중국, 미국, 스페인, 헝가리, 이스라엘, 대한민국, 대만, 벨기에, 오스트리아, 러시아 연방, 스위스, 포르투갈, 프랑스, 캐나다, 이탈리아, 영국, 그리스, 일본, 독일, 스웨덴
-
Daiichi SankyoDaiichi Sankyo Korea Co., Ltd.모집하지 않고 적극적으로
-
Daiichi SankyoAstraZeneca; Daiichi Sankyo Co., Ltd.모집하지 않고 적극적으로유방암미국, 스페인, 이스라엘, 이탈리아, 대한민국, 벨기에, 호주, 체코, 일본, 브라질, 프랑스, 영국, 칠면조, 그리스, 독일
-
Daiichi Sankyo Co., Ltd.완전한